• Implemented ARR increased by 5.9% to $4.46 million
• Customer receipts rose 27% to $1.284 million
• First commercial deployments in the US under Sabra agreement
• Net operating cash outflow improved to $1.791 million
• Cash position strengthened with $5.5 million convertible note and $1.123 million R&D Tax Incentive refund

PainChek Ltd. (ASX: PCK) reported its quarterly activities and Appendix 4C for the three months ended 30 June 2026. The company saw a 5.9% increase in implemented annual recurring revenue (ARR) to $4.46 million, driven by a 4,998 increase in implemented licenses to 90,198. Customer receipts rose 27% to $1.284 million, primarily due to increased customer activations. PainChek secured its first commercial deployments under the Sabra master services agreement in the United States, marking the beginning of commercial outcomes from established market access. The company also improved its net operating cash outflow by $689,000 to $1.791 million and strengthened its cash position with a $5.5 million convertible note and a $1.123 million R&D Tax Incentive refund.